FLQ 104
Alternative Names: FLQ-104Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator FELIQS
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Ferroptosis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration; Wet age-related macular degeneration
Most Recent Events
- 06 Nov 2024 Preclinical trials in Dry age-related macular degeneration in Japan (PO), before November 2024 (FELIQS pipeline, November 2024)
- 06 Nov 2024 Preclinical trials in Wet age-related macular degeneration in Japan (PO), before November 2024 (FELIQS pipeline, November 2024)
- 01 Nov 2024 FELIQS plans to submit IND application for Dry age related macular degeneration (PO), in second half of 2025